BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 10967572)

  • 21. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.
    Nakazawa Y; Saito S; Hasegawa Y; Yanagisawa R; Sakashita K; Kamijo T; Miyazaki T; Sato S; Ikeda H; Ikebuchi K; Koike K
    Transfusion; 2007 Feb; 47(2):326-34. PubMed ID: 17302780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission.
    Lee DH; Kwon YJ; Lim J; Kim Y; Han K; Chung NG; Jeong DC; Cho B; Kim HK
    Pediatr Transplant; 2009 Mar; 13(2):210-6. PubMed ID: 18627512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.
    Schetelig J; Bornhäuser M; Schmid C; Hertenstein B; Schwerdtfeger R; Martin H; Stelljes M; Hegenbart U; Schäfer-Eckart K; Füssel M; Wiedemann B; Thiede C; Kienast J; Baurmann H; Ganser A; Kolb HJ; Ehninger G
    J Clin Oncol; 2008 Nov; 26(32):5183-91. PubMed ID: 18768435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia.
    Geiger TL; Woodard P; Tong X; Srivastava DK; Johnson R; Turner V; Hale G; Richardson S
    Br J Haematol; 2002 Jun; 117(3):634-41. PubMed ID: 12028035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
    Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.
    Sartor MM; Garvin F; Antonenas V; Bradstock KF; Gottlieb DJ
    Bone Marrow Transplant; 2007 Nov; 40(9):851-7. PubMed ID: 17704793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
    Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U
    Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
    Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
    Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.